Clinical Trials
143 trialsFruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
RemeGen Co., Ltd.
the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer
RenJi Hospital
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma
West China Hospital
Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer
The First Hospital of Jilin University
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection
Fujian Medical University Union Hospital
Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer
Tang-Du Hospital
IMPROVE
Fudan University
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Third Affiliated Hospital, Sun Yat-Sen University
RAIC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Zhejiang Cancer Hospital
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Zhejiang Cancer Hospital
The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.
China Three Gorges University, Yichang, China
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
RenJi Hospital
Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer
Fudan University
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Sun Yat-sen University
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab
Xiangya Hospital of Central South University
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
EP-STAR
Sun Yat-sen University
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
Innovent Biologics (Suzhou) Co. Ltd.
CONTINUUM
Sun Yat-sen University
CASTLE-08
Fudan University
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma
China Three Gorges University, Yichang, China
Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study
Sun Yat-sen University
Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
Fudan University
Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
Tianjin Medical University Cancer Institute and Hospital
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Beijing Tsinghua Chang Gung Hospital
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer
Fudan University
SPBPDC
Qianfoshan Hospital
TRUMP
Guangdong Association of Clinical Trials
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
REGSIN
Second Affiliated Hospital of Guangzhou Medical University
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
The First Affiliated Hospital with Nanjing Medical University